Skip to content

Sorafenib

    Brands

    DEA Class; Rx

    Common Brand Names; Nexavar

    • Antineoplastics, Tyrosine Kinase Inhibitor; 
    • Antineoplastics, VEGF Inhibitor

    Multi-kinase inhibitor targeting several intracellular and cell surface kinases
    Used for the treatment of hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid cancer refractory to radioactive iodine treatment
    Dermatologic toxicities are among the most common adverse reactions associated with sorafenib treatment and may require an interruption of therapy or dose reduction

    Indicated for advanced renal cell carcinoma

    Indicated for unresectable hepatocellular carcinoma

    Indicated for locally recurrent or metastatic, progressive, differentiated thyroid cancer (DTC) that is refractory to radioactive iodine treatment

    Hypersensitivity

    Coadministration with carboplatin and paclitaxel in patients with squamous cell lung cancer

    • Thrombocytopenia (12-46%)
    • Anemia (44%)
    • Diarrhea (43%)
    • Rash/desquamation (40%)
    • Fatigue (37%)
    • Abdominal pain (31%)
    • Hand-foot skin reaction (30%)
    • Weight loss (30%)
    • Anorexia (29%)
    • Alopecia (27%)
    • Nausea (24%)
    • Lymphopenia (23%)
    • Neutropenia (18%)
    • Hemorrhage (15-18%)
    • Hypertension (9-17%)
    • Vomiting (16%)
    • Constipation (15%)
    • Neuropathy (13%)
    • Dry skin (11%)

    Osteonecrosis of jaw reported

    Increased risk of cardiac ischemia/HTN/hemorrhage; consider temporary or permanent discontinuation of therapy in patients who develop cardiovascular events

    Withhold therapy for at least 10 days prior to elective surgery; do not administer for at least 2 weeks following major surgery and until adequate wound healing; safety of resumption of therapy after resolution of wound healing complications has not been established

    Hepatitis reported; characterized by a hepatocellular pattern of liver damage with significant increases of transaminases which may result in hepatic failure and death

    QT Prolongation: Monitor for prolonged QT intervals with CHF, bradyarrhythmias, drugs known to prolong QT interval, and electrolyte abnormalities; avoid with congenital long QT syndrome

    Congestive heart failure reported; temporary or permanent discontinuation of therapy should be considered in patients who develop cardiovascular events

    Monitor blood pressure weekly during first 6 weeks and periodically thereafter; consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy

    Avoid pregnancy

    High incidence of skin toxicity and rash

    There are no available data in pregnant women to inform a drug associated risk

    There are no data on presence of drug or its metabolites in human milk, or its effects on breast-fed child or on milk production

    Adults

    800 mg/day PO.

    Elderly

    800 mg/day PO.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Sorafenib 

    tablet

    • 200mg